Top Pharma Conferences | Pharmacovigilance Conferences | Clinical Trials Conferences

Theme:

Drug Safety 2020

Scientific Program

Renowned Speakers

Hanan Fael
KoÃ§ University,
Turkey

Kostas Demadis
University of Crete
Greece

Margitta Dathe
Leibniz-Forschungsinstitut fÃ¼r Molekulare Pharmakologie
Germany

Fiorenza Rancan
CharitÃ© â€“ UniversitÃ¤tsmedizin
Germany

Stefan Bughi
Rancho Los Amigos National Rehabilitation Center
USA

Volkmar Weissig
World Mitochondria Society
USA

Pamela Georgina Avila Lamadrid
Instituto Politecnico Nacional,
Mexico

Khuloud Al-Jamal
Kings College London,
UK

Gulnara Khakimova
NPF â€Materia Medica Holding,
Russia

Shayan F Lahiji
Yonsei University,
South Korea

Edgar PÃ©rez-Herrero
University of Salamanca,
Spain

Achim Aigner
Leipzig University,
Germany

Christina Yuen Ki Leung
The University of Hong Kong-Shenzhen Hospital, China
China

Blessing Aderibigbe
University of Fort Hare,
South Africa

Ndidi Ngwuluka
University of Jos,
Nigeria

Tatsuya Takagi
Osaka University,
Japan

Alexei Basnakian
DNA Damage and Toxicology Core Center University of Arkansas
USA

Mitsuji Yamashita
Shizuoka University,
Japan

Margitta Dathe
Leibniz-Forschungsinstitut fÃ¼r Molekulare Pharmakologie,
Germany

Ilayda Acaroglu Degitz
Yeditepe University,
Turkey

Drug Safety 2020

14th International Conference on Pharma and Drug Safety will be held in October 21-22, 2020 as a virtual confernce (webinar). Drug Safety 2020 is a worldwide stage for drug specialists, pharmaceutical advertising professional's, pharmaceutical industry experts, and analysts, researchers, clinicians, scholastics, Delegates, graduates and other expert speakers. The fundamental objective of the conference is to advance the new progressions, research, and improvements, investigate the difficulties in Pharmacy and Pharmaceutical Science and related areas.

There is a prerequisite to improve, instruct and update the information and abilities of pharmaceutical organization experts working in rapidly adjusting pharmaceutical business. At this lofty occasion, the members will expect taking part sessions on inclining subjects other than included interactions, sessions, and business symposiums. The worldwide prestigious speakers from different countries can share their significant bits of knowledge on the progressions in pharmaceutical sciences. Driving pharmaceutical partnerships are relied upon to take part to show their most recent pharmaceutical delivering forms, advances, and amazing apparatus.

The Conference will have an intensive 2-day event with a wide scope of theme “Execution of Research, Innovation and Ideas of Drug Safety, Pharmacovigilance and Pharmaceutics” covering drug store practice, pharmaceutical science, pharmacology, pharmacovigilance, and numerous other pharmaceutical improvements. The meeting additionally gives proceeding with expert improvement credits to every one of the members which demonstrate that they are skilled in their field. Drug Safety 2020 scientific program includes Workshops, scientific sessions, Sub-sessions, poster presentation and short oral presentation competitions.

Target Audience

Pharmacists
Pharmaceutical Researchers
Professors and Associate Professors
Directors and CEO’s of Organizations
Pharmaceutical societies, Associations
Physicians and clinical pharmacists
Pharmacologists
Nanotechnologists
Pharmaceutical societies
Biomedical Engineers
Biotechnologists
Cosmetic companies
Medicinal and Pharmaceutical companies
Medical Devices Companies
Research Institutes and members
Supply Chain companies
Manufacturing Companies
Clinical Research Organizations
Regulatory Authorities
Training Institutes
Entrepreneurs
Clinical Pharmacologists
Clinical Toxicologists
Drug Manufacturers

14th International Conference on Pharmaceutics and Drug Safety is among the world's leading pharmaceutical conference. The two-day occasion on pharmaceutical sciences will have 60+ logical and particular sessions and sub-sessions on innovative researches in the field of pharmaceutical sciences over the globe. Drug Safety 2020 will involve 16 imperative sessions proposed to offer broad sessions that states issues in the diverse fields of research and pharmaceutical sciences.

The attendees can find exclusive sessions and panel discussions on latest innovations in Pharma and Pharmaceutical Sciences.

- Lectures from renowned speakers

- Keynote forums by Prominent Professors, Doctors

- Open Innovation Challenges

- Poster presentations by Young Researchers

- Global Networking sessions with 50+ Countries

- Novel techniques to benefit your research

- Best platform for Global business and Networking opportunities

- Meet the editors of referred journals, Society and Association members across the Globe

- Excellent platform to showcase the latest products and formulations in Pharma Care

Track 1: Pharmaceutical Sciences

The Pharmaceutical Science is an expansive scope of logical controls that are basic to the disclosure and advancement of new medications and treatments. Pharmaceutical sciences might be a dynamic and learning base field that expects to incorporate fundamental standards of physical and compound science, designing, organic chemistry, and science to see how to upgrade conveyance of medications to the body and make an interpretation of this coordinated comprehension into as good as ever treatments against human ailment. There are numerous looks into going on so as to improve the human wellbeing some of them are the advancement and assessment of new medication conveyance techniques; pharmaceutical, metabolomic and proteomic examination of biomarkers in malignant growth; new drug for the treatment of uncommon metabolic infections, for example, cystinosis, and the counteractive action of chemotherapy prompted sickness. Extra work is furthermore viewing the successful utilization of prescriptions and in this way the examination of drugs audit as far as protected and viable treatment.

Related Conferences: 18th World Pharma Congress during October 18-20, 2020 Warsaw, Poland | 4th International Conference on Drug Discovery and Advanced Drug Delivery Systems conferences, October 18-19, 2020 at Warsaw, Poland | 18th Annual Pharmaceutical Chemical Analysis Congress, November 05-06, 2020 at Madrid, Spain | 9th Neuropharmacology Meeting during November 15-16, 2020 at Frankfurt, Germany | 3rd International Conference on Generics Drugs and Biosimilars Conferences, November 15-17, 2020 at Frankfurt, Germany | 23rd International Pharmaceutical Biotechnology Conference, December 10-11, 2020 at Rome, Italy | 19th Pharmaceutical Sciences and Pharma Industry Conference February 25-26, 2020, Berlin, Germany | 12th European Biosimilars Congress April 15-16, 2020 Berlin, Germany

Track 2: Drug Safety and Pharmacovigilance

Drug safety relates to the potential for adverse effects related to the administration of drugs. Efforts to establish the safely profile of drugs begin early in their development, with in vitro and in vivo toxicity testing, and continue through clinical trials leading up to drug approval and following approval in specific post-marketing studies or general pharmacovigilance efforts

Pharmacovigilance (PV or PhV), also known as drug safety, is the pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products.The etymological roots for the word "pharmacovigilance" are: pharmakon (Greek for drug) and vigilare (Latin for to keep watch). As such, pharmacovigilance heavily focuses on adverse drug reactions, or ADRs, which are defined as any response to a drug which is noxious and unintended, including lack of efficacy (the condition that this definition only applies with the doses normally used for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological disorder function was excluded with the latest amendment of the applicable legislation). Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction

Signal Detection in Drug Safety
Consulting on Risk Management
Adverse Event Reporting
Postmarketing Drug Safety

Track 3: Clinical Trials and Research

Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison. Clinical trials generate data on safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial their approval does not mean that the therapy is safe or effective, only that the trial may be conducted

Research Methodology
Recent Updates on Clinical Trials
Clinical Molecular Genetics
Clinical Immunology
Clinical Drug Development and Therapeutics
Clinical Research and Methodology

Track 4: Adverse Drug Reactions

Adverse drug reactions can be considered a form of toxicity or enhanced drug effects that occur during appropriate use (eg, when drug metabolism is temporarily inhibited by a disorder or another drug). In the US, 3 to 7% of all hospitalizations are due to adverse drug reactions. ADRs occur during 10 to 20% of hospitalizations; about 10 to 20% of these ADRs are severe. Incidence of death due to ADRs is unknown; suggested rates of 0.5 to 0.9% may be falsely high because many of the patients included had serious and complex disorders. Incidence and severity of adverse drug reactions vary by patient characteristics (eg, age, sex, ethnicity, coexisting disorders, genetic or geographic factors) and by drug factors (eg, type of drug, administration route, treatment duration, dosage, and bioavailability). Incidence is higher with advanced age and polypharmacy.

Track 5: Pharmacovigilance and Risk Management

Pharmacovigilance and Risk Management comprises set of pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to medicinal and therapeutic products including the assessment of the effectiveness of their clinical interventions and combination therapies. Drug industry need to promote companies in pharmacovigilance practice to use information technology and to review softwares used in pharmacovigilance and clinical trials. Monitoring unlicensed, off labels and orphan drugs is major task in risk management. Many experts from different pharmacovigilance CRO's , pharmacovigilance service providers and industrial delegates are participating in this conference to share their knowledge and discuss about the new updates.

Track 6: Biopharmaceutical Sciences

In Clinical Pharmacology and Biopharmaceutics track we will discuss about the Rational drug management of cancer, diabetes and cardiovascular disorders, and Management of psychiatric disorders and autoimmune disorders. Along with clinical trials Bioavailability and bioequivalence studies also plays major role in clinical research. The global market for Bio pharmaceutics in 2013 was $305.1 million, which is expected to reach about $326.3 million by year-end 2014. The projected PAT instrumentation market is expected to be valued at around $450.6 million by 2019 at a compound annual growth rate (CAGR) of 6.7% for the period of 2014 to 2019.

Track 7: Clinical Trials on Various Disorders

Clinical Trials on various diseases include Clinical Trials in long chronic diseases like AIDS, Benign and Malignant Tumours, Cardiovascular diseases, Diabetes, Clinical Trials on Monoclonal and Polyclonal Antibodies, Neurological, Physiological and Psychological Disorders.

Track 8: Data Quality Management and Analysis

Good data quality management in pharmacovigilance can be relied only on information gathered from the collection of individual case safety reports and other pharmacoepidemiological data. Quality management consists of quality planning, quality control, quality assurance and quality improvements. The pharmacovigilance data processing cycle starts with data collection and, in computerised systems, data entry; the next step is data storage and maintenance; followed by data selection, retrieval and manipulation. The resulting data output is analysed and assessed. Finally, conclusions are drawn and decisions are made. The quality of a pharmacovigilance data system can be defined as a measure of excellence or a state of being free from defects, deficiencies and significant variations and the data quality management includes all the activities that organizations use to direct, control and coordinate the quality of data.

Track 9: Drug Safety

Drug Safety heavily focuses on adverse drug reactions which are defined as any response to a drug which is noxious and unintended, including lack of efficacy. Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction.

Information received from patients and healthcare providers via pharmacovigilance agreements (PVAs), as well as other sources such as the medical literature, plays a critical role in providing the data necessary for pharmacovigilance to take place. Ultimately, drug safety is concerned with identifying the hazards associated with pharmaceutical products and with minimizing the risk of any harm that may come to patients. Companies must conduct a comprehensive drug safety and pharmacovigilance audit to assess their compliance with worldwide laws, regulations, and guidance.

Track 10: Pharma Manufacturing and Compliance

Drug manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs by pharmaceutical companies. The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.

Good manufacturing practice guidelines provide guidance for manufacturing, testing, and quality assurance in order to ensure that a manufactured product is safe for human consumption or use. Many countries have legislated that manufacturers follow GMP procedures and create their own GMP guidelines that correspond with their legislation. All guideline follows a few basic principles.

Regulatory Compliance
Risk Management
Patient Compliance
Data Integration

Track 11: Regulatory Affairs and Intellectual Property Rights

Intellectual property (IP) is a category of property that includes intangible creations of the human intellect.Intellectual property encompasses two types of rights: industrial property rights (trademarks, patents, designations of origin, industrial designs and models) and copyright.It was not until the 19th century that the term "intellectual property" began to be used, and not until the late 20th century that it became commonplace in the majority of the world

Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc. Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).

Regulatory affairs (medical affairs) professionals (aka regulatory professionals) usually have responsibility for the following general areas;

Working with federal, state, and local regulatory agencies and personnel on specific issues affecting their business, i.e., working with such agencies as the Food and Drug Administration or European Medicines Agency (pharmaceuticals and medical devices); The Department of Energy; or the Securities and Exchange Commission (banking).

Advising their companies on the regulatory aspects and climate that would affect proposed activities. i.e. describing the "regulatory climate" around issues such as the promotion of prescription drugs and Sarbanes-Oxley compliance.

The Agreement provides norms and standards in respect of following areas of intellectual properties are Patents, Trademarks, copyrights, Geographical indications, Industrial designs.

Drug Regulations and Organizations
Regulations and Organizations
Global Pharma Products Registration
Intellectual Property Law for Generics and Innovator Rights
Safety and Quality Regulation in Labelling
Antimicrobial Activity and Disinfection

Track 12: Drug Formulation & Analytical Techniques

Pharmaceutical formulation in pharmaceutics is the process in which various chemical substances including the vigorous drug are joined to produce a final medicinal product. Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally taken drugs, this usually contains combining the drug into a tablet or a capsule. Formulations confirm that the drug is compatible with these other substances. In the pharmaceutical drug formulations, the different physical, chemical, and mechanical properties of a drug are considered so as to know what other ingredients should be used in the preparation. The various factors like polymorphism, particle size, pH, and solubility are all considered while formulating the drug, also considering the appearance of the tablet.

Formulation Types
Sources of Drug Formulation
Advanced Formulation Techniques
Chromatography Techniques
Spectroscopy Techniques
Electrochemical Methods
Titrimetric Techniques

Track 13: Pharmaceutical Technology

Pharmaceutical Technology is the regulation of pharmacy that assign with the process of turning an Active Pharmaceutical Ingredient (API) into a medication to be used by patients. It is also a knowledge base to pharmacy, pharmacology and also pharmaceutical business. It describes designs, techniques, instrumentation in the preparation, manufacturing, compounding, packaging, dispensing, accumulating of narcotic and other preparations used in determinative and diagnostic e procedures in the treatment of patients. It is additionally associated with the science of dose type

Medical Practitioners
Drug Inspectors
Drug Analysts
Technology Transfer
Pharmaceutical Technology Assessment
Quality assurance
Bioinformatics and Computational Biology
Pharmacological Technology Advances
Pharmaceutical Packaging and labelling

Track 14: Pharmaceutical Care

Pharmaceutical care is defined as the responsible provision of drug therapy for the purpose of achieving definite therapeutic outcomes that improves the patients quality of life. It involves the process through which a pharmacist cooperates with patients and other professionals in designing, implementing and monitoring a therapeutic plan will produce specific therapeutic outcomes for the patients.

Patient Safety
Emergency Care
Safety Assessment
Pharmaceutical Care Management
Medication Management Services

Track 15: Drug Regulations

Drug regulation is the control of drug use by international agreement and/or by regulatory authorities such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceutical and Medical Devices Agency (PMDA).

Track 16: Quality Assurance

Quality assurance is a way of preventing mistakes and defects in manufactured products and avoiding problems when delivering products or services to customers; which ISO 9000 defines as "part of quality management focused on providing confidence that quality requirements will be fulfilled.

Track 17: Data Quality Management & Analysis

It covers the discipline and practice of Data Quality Management (DQM) in a multi-domain Master Data Management (MDM) framework. It discusses how to define and apply a DQM model consistently across a multi-domain environment, and how to expand the practice of DQM to an enterprise level. This chapter starts by presenting how DQM fits into a multi-domain MDM environment and how important it is to manage DQM strategies, decisions, and execution. It continues by introducing a DQM model that is critical to supporting and scaling the discipline beyond MDM. Finally, it covers a data-quality improvement life cycle, with the required steps and activities to analyze, plan, execute, and monitor data quality projects effectively and efficiently.

Data Profiling
Data Reporting
Data Repair
Defining data quality

Track 18: Prevalence of Potential Drug- Drug Interaction

The objective of this study is to estimate the prevalence and describe the characteristics of pDDIs in medical prescriptions of hospitalized surgical patients. In this cross-sectional study, we analyzed 370 medical prescriptions from the surgery unit of a Mexican public teaching hospital. The identification and classification of potential drug-drug interactions were performed with the Micromedex 2.0 electronic drug information database. Results were analyzed with descriptive statistics and we estimated OR (odds ratio) to determine associated risk factors.

Track 19: Pharmacoepidemiology

Pharmacoepidemiology is the study of the uses and effects of drugs in well-defined populations. To accomplish this study, pharmacoepidemiology borrows from both pharmacology and epidemiology. Thus, pharmacoepidemiology is the bridge between both pharmacology and epidemiology. Pharmacology is the study of the effect of drugs and clinical pharmacology is the study of effect of drugs on clinical humans. Part of the task of clinical pharmacology is to provide a risk benefit assessment by effects of drugs in patients:

doing the studies needed to provide an estimate of the probability of beneficial effects on populations,
or assessing the probability of adverse effects on populations.

Track 20: Recent trends in Pharma and Technology

Every industry is changing at a more fast pace. Products and administrations are getting to be progressively commercialized. Innovation is playing a continuously greater part in inquire about and improvement, showcasing and promoting, and deals and dispersion. The pharmaceutical division is one that has felt this change in investigate and advancement over the past few years and will begin to feel it within the other divisions over the another decade. It's exceptionally likely that within the next decade, people will now not be pharmaceutical test subjects. Instead, cognitive computers will be utilized in biotechnology and genomic research. Instead of it taking months to see the impact of a specific drug on thousands of individuals, it'll take seconds to see the impact of thousands of drugs on billions of simulations of the human body's physiology. Body sensors are a new innovation that's right now still in clinical trials. These sensors can either be put on the body or interior of it. They degree different basic crucial signs. With the unused innovation and advancement, patients are picking up more control. They presently have the capacity to have more of a say when it comes to their body and their health. In this way, pharmaceutical companies will have to be starting taking patient needs, thoughts, and desires into consideration. Products will be more effective if patients are included in their creation and distribution. It's likely that over the coming a long time, numerous companies within the pharmaceutical industry will make persistent admonitory sheets. The pharmaceutical industry is changing at each an each level.

Phenotypic Screening
Organs -On-A-Chip
Bioprinting
New Antibiotics Discovery
Adoption of Artificial Intelligence by Pharma and Biotech

There has been associate degree upsurge within the usage of advanced technologies, like high turnout, bioinformatics and combinatorial chemistry for higher drug candidate identification. Drug discovery has evolved considerably with rising technologies, serving to the method to become a lot of refined, accurate, and fewer time overwhelming. Thanks to automation, multi-detector readers, imaging hardware and software package, high-throughput screening is one amongst the foremost wide used drug discovery technologies.

In recent years, there has been a rising demand for specialty medicines that's expected to ultimately influence the little molecule drug discovery market in a very positive manner, as most of the specialty medicines area unit tiny molecules.

The gradual rise within the health care expenditure regionally helps the new pharmaceutical technology advancement. Though with high expenditure, there's a desire for redirecting the resources, the transition toward higher usability of health care expenditure for drug development is below progress.

Scope and Importance of Pharmaceutical Sciences:

The scope of pharmacy follow includes combining and dispensing medications, and it put together related to plenty of trendy services like patient care, clinical services, reviewing medications for safety and powerfulness, and put together providing and gaining the drug knowledge.

A Glance at Market of Pharmaceutical Sciences:

The power of worldwide pharma has been growing over the past year, keep with the annual survey conducted Worldwide. Throughout the last ten to fifteen years, deals among the worldwide Nutrition supplements market have seen associate degree exceptional spike. The pharmaceutical business may be a crucial player in United Kingdom, Great Britain and Northern Ireland. In 2017, the annual turnover of pharmaceutical product wholesalers among the uk was over forty 2 billion British pounds, whereas the income from the retail sales of pharmaceutical product amounted to just about five billion British pounds in 2015. the price among the manufacturing of pharmaceutical product came up to over four billion in 2019.

Growth potential

India (7.16), the U.S. (7.04) and China (6.81) area unit once more the countries highlighted as having the quickest growth potential. Respondents viewed their high growth domestic markets and increasing producing exports as successful. Federal Republic of Germany was seen as Europe’s key growth market. the largest movers in terms of growth potential compared to last year were the united kingdom, boosting its score by twelve.72%, followed by Italian Republic (+10.94%), the U.S. (+10.63%) and Japan (+9.56%).

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	October 21-22, 2020
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed
Poster Opportunity Closed	Click Here to View

14^th International Conference on Pharmaceutics and drug safety October 21-22, 2020 Frankfurt, Germany

Recommended Global Pharmaceutical Sciences Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links

Renowned Speakers

Drug Safety 2020

Track 1: Pharmaceutical Sciences

Conference Highlights

To Collaborate Scientific Professionals around the World

Useful Links

Special Issues